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Abstract 
4Z,15Z-bilirubin-IXα (4Z,15Z-BR), an endogenous compound that is sparingly soluble in water, binds 
human serum albumin (HSA) with a high-affinity in a flexible manner. A phage library displaying 
recombinant HSA-domain II was constructed, after three rounds of panning against immobilized 4Z,15Z-BR, 
and eight clones with a high affinity for the pigment were found to contain conserved basic residues such as 
lysine or arginine in positions 195 and 199. A wild type and two mutants, K195A and K199A, of whole HSA 
as well as standalone domain II, were expressed with Pichia pastoris for ligand binding studies. The binding 
of 4Z,15Z-BR to the K195A and K199A mutants was decreased in both whole HSA and the domain II 
proteins. The P-helicity conformer (P-form) of 4Z,15Z-BR was found to preferentially bind to the wild types 
and the K195A proteins whilst the M-form binds to the K199A mutants. Photoconversion experiments 
showed that the P-form of 4Z,15Z-BR was transformed into highly water soluble isomers at a much faster 
rate than the M-form. In addition, the M-form of 4Z,15Z-BR was found to bind to domain I with a lower 
affinity than domain II. The present findings suggest that whilst both Lys195 and Lys199 in subdomain IIA 
are important for the high affinity binding of 4Z,15Z-BR, Lys199 plays a more prominent role in the 
elimination of 4Z,15Z-BR.  
 









Bilirubin, which is produced during the catabolism of hemoglobin, can exist in several isomeric forms 
[1]. 4Z,15Z-bilirubin-IXα (4Z,15Z-BR) is the main isomer in the body and can cause kernicterus in newborns. 
The neurotoxicity of 4Z,15Z-BR is most probably related to its extremely low solubility in water at neutral 
pH [2]. The neurotoxicity of the pigment is diminished, and its solubility in aqueous media is increased on 
binding to human serum albumin (HSA), to which it binds with a high-affinity constant in the order of 
107-108 M-1. Hydrogen bonds, aromatic π–π and hydrophobic interactions are important for binding [3, 4]. 
On the other hand, the conversion of 4Z,15Z-BR to 4Z,15E-BR by photosentization results in the formation 
of a geometric isomer that has a lower binding affinity to HSA but a higher water solubility, which permits it 
to be excreted more easily than the precursor 4Z,15Z-BR [5]. 
HSA is the most abundant protein in plasma and is responsible for most of the oncotic pressure. It is a 
simple protein without prosthetic groups and does not contain any glycan chains and, hence, is not a 
glycoprotein. It is a heart-shaped protein comprised of three homologous domains, each of which is further 
divided into two subdomains A and B [6]. HSA binds a variety of different endogenous substances such as 
fatty acids, bilirubin, various uremic toxins and thyroxines. Two discrete drug binding sites designated as 
Sudlow Site I and Site II have also been found on subdomains IIA and IIIA, respectively [6]. 
Affinity binding experiments of 4Z,15Z-BR with albumin fragments point to a fragment comprised of 
amino acid residues from about 180 to 250, which roughly correspond to subdomain IIA [7]. Petersen et al. 
[8] studied the binding of 4Z,15Z-BR to eight different HSA mutants in which amino acids assumed to be 
important for binding had been mutated. Surprisingly, none of the single-amino acid substitutions had any 
significant effect on the binding of 4Z,15Z-BR. This result was taken to indicate the existence of a dynamic, 
unusually flexible high-affinity binding site for 4Z,15Z-BR in subdomain IIA. In addition, the bisignate CD 
 
 
spectra of 4Z,15Z-BR becomes inverted when 4Z,15Z-BR binds to various mammalian albumins with more 
than an 80% homology with HSA [9].  
In thermodynamic studies of interactions of 4Z,15Z-BR and HSA, ΔH° and ΔS° were found to be -13.5 
kcal / mol and -0.0085 kcal / mol / K, respectively [3]. The large negative free energy for the interaction, 
which is mainly the result of a large enthalpy change, suggests the importance of electrostatic rather than 
hydrophobic interactions. Earlier studies proposed that the bound BR interacts with histidine, arginine, 
tyrosine [10] and lysine residues [11-14], especially buried lysine residues [15], but not with Lys240 [16]. 
Hence, salt linkages between the carboxyl groups of BR and ε-NH2 groups of lysine residues of HSA appear 
to be necessary for the binding of BR [10, 17]. Therefore, it is highly possible that the multiple pattern 
binding mode is due to the formation of a flexible 4Z,15Z-BR-HSA complex, and that no single crucial 
binding mode exists, but multiple interactions are ongoing between 4Z,15Z-BR and HSA [11-17]. In order to 
conduct a binding site topology analysis, it becomes necessary to simultaneously introduce multiple 
mutations into domain II. However, one of the inherent limitations of point mutation techniques is that it 
requires the selection of a reasonably small number of residues as targets. To overcome this limitation, phage 
display technology, which can be used to efficiently perform multiple mutations, represents an alternative 
and potentially useful approach. Phage display is a powerful technology for identifying polypeptides with 
novel properties, and altering the properties of existing ones [18-22]. Phage display has been used in epitope 
mapping and studies of protein-protein interactions. This technique involves the insertion of a foreign DNA 
fragment in the structural gene of a bacteriophage, which leads to the expression of a peptide or protein at the 
surface of the viral particle. The rapid isolation of specific ligands by phage display is advantageous in many 
applications, including the selection of inhibitors for active and allosteric sites of enzymes, receptor agonists 
and antagonists, and specific ligands isolated from phage libraries can also be used in therapeutic target 
validation, drug design and vaccine development. The use of this technology to identify amino acid residues 
that are involved in ligand binding is not uncommon. The purpose of this study was to identify the functional 
amino acid residues in HSA that play a role in high-affinity 4Z,15Z-BR binding by constructing a phage 
display library using the M13 phage. We selected domain II that contains the binding site of 4Z,15Z-BR as 
the display protein. Since electrostatic interactions have been shown to be an important factor in the binding 
 
 
of 4Z,15Z-BR to HSA, we screened the role of two positively charged amino acid residues, namely lysine 
and arginine, which could potentially participate in electrostatic interactions with the carboxylate groups of 
4Z,15Z-BR.  
Results 
Construction of a Phage Library displaying HSA-domain II 
We initially displayed the wild type HSA-domain II (residues 187-385, 22 kDa) on the M13KO7 phage, 
as described in the Experimental Procedures section. The expression of the HSA-domain II on the phage was 
confirmed by an enzyme-linked immunosorbent assay (ELISA). Both the HSA-domain II displaying phage 
and the M13KO7 helper phage were equally reactive against the anti-M13KO7 antibody, while only the 
HSA-domain II displaying phage showed specific activity for the anti-HSA polyclonal antibody (Fig. 1). 
These results confirm that the HSA-domain II is displayed on the M13 phage. In the second phase of this 
study, we constructed a phage library displaying mutated versions of recombinant HSA-domain II. Because 
4Z,15Z-BR contains two carboxyl groups, previous researchers have proposed that basic residues, lysine 
and/or arginine, are key residues that interact with the carboxyl groups of 4Z,15Z-BR via salt bridge 
formation [11-16]. To test this hypothesis and to identify the positions of such key residues, the eight lysines 
and four arginines located in subdomain IIA were randomly substituted with basic lysine or arginine, neutral 
glycine or acidic glutamic acid residues. To produce these substitutions, the lysine and arginine codons were 
replaced with RRA (where R represents A / G) in the cDNA library. Because RRA encodes only four codons 
(AAA: Lys, AGA: Arg, GAA: Glu, GGA: Gly), the bias of this library can be assumed to be insignificant. 
As shown in Figure S3, the sequences of unselected 24 phages, displayed little or no bias. The library 
contained approximately 1.7 × 107 phage clones, a size that covers all potential clones that can be expressed.  
 
Biopanning and Evaluation of 4Z,15Z-BR Binding Capacity of Selected Clones 
In order to identify the recombinant HSA-domain II displaying phages with high 4Z,15Z-BR binding 
affinities, the phage library was subjected to three rounds of panning against 4Z,15Z-BR immobilized on an 
EAH Sepharose 4E gel. The recovery rate of each round was calculated and are listed in Table 1. After the 
third panning, 111 phage clones were isolated, and their binding affinity to 4Z,15Z-BR was evaluated by an 
 
 
HRP assay. Among these 111 clones, 15 were found to bind 4Z,15Z-BR with the same or a higher affinity as 
wild type domain II (data not shown). A DNA sequencing analysis of these clones showed that 7 clones had 
frame shifts caused by nucleotide deletions or mutations and did not retain a complete domain II sequence. 
These deletions and mutations are the result of the fact that the phagemid vector contains a single-stranded 
DNA, which is relatively unstable, and/or that the HSA sequence has a stretch of five A bases which is a 
spontaneous mutational “hot spot” [23]. The remaining 8 clones retained the sequence of domain II and were 
numbered serially (Fig. 2A). As seen from the figure 2A, one of the clones (No. 7) has the same amino acid 
sequence as wild type domain II. It is noteworthy that a DNA sequencing analysis of these 8 clones showed 
that 7 of them contain a basic amino acid residue at position 195, and that all of the 8 clones contain a basic 
residue at position 199 (Fig. 2A).  
The above findings were confirmed by the following experiments. First, the proteins of the 8 selected 
clones were expressed using the Pichia pastoris protein expression system and purified. Their 4Z,15Z-BR 
binding capabilities were then evaluated by the HRP assay. As can be seen in figure 2B, all of the mutated 
domains bound 4Z,15Z-BR equally well and with an affinity comparable to that of wild type domain II (No. 
7). These results suggest that Lys195 and Lys199 in domain II of HSA are important amino acid residues in 
the binding of 4Z,15Z-BR via electrostatic interactions.  
 
Effects of Lys195 and Lys199 mutations to alanine on the binding of 4Z,15Z-BR to domain II and HSA 
Wild type domain II and domains with the K195A or K199A mutations were produced, and their 
4Z,15Z-BR binding activities determined by a HRP assay. Both mutants, but especially domain II-K199A, 
had a significantly lower affinity for 4Z,15Z-BR than wild type domain II (Fig. 3A). Consistent with the 
domain II studies, both point mutations, K195A and K199A, resulted in significantly weaker 4Z,15Z-BR 
binding to full body HSA mutants (Fig. 3B).   
The interaction of 4Z,15Z-BR with full body HSA and mutants was also investigated by fluorescence 
spectroscopy. The binding constant (Ka) for wild type HSA was determined to be 5.03 ± 0.53 × 107 M-1 
(Table 2). This value is reasonably consistent with the value for the high-affinity binding constant of 1.56 × 
107 M-1 reported by Petersen et al. [8], who used a peroxidase protection assay, and to that (1.10 × 108 M-1) 
 
 
determined by Minchiotti et al. [16], who used fluorescence quenching titration. The Ka-values for binding 
to mutants K195A and K199A were calculated to be 1.10 ± 0.32 × 107 M-1 and 1.01 ± 0.15 × 107 M-1, 
respectively (Table 2). Thus, the two point mutations both resulted in a 5-fold reduction in binding affinity 
for 4Z,15Z-BR. 
 
Binding conformation of 4Z,15Z-BR to wild type and mutant proteins of domain II and HSA examined 
with CD spectroscopy 
Figure 4B shows that the binding of 4Z,15Z-BR to wild type domain II results in an induced 4Z,15Z-BR 
-CD spectra typical for the P enantiomer of 4Z,15Z-BR (Fig. 4B). Introduction of the K195A mutation had 
little effect on the spectra. In contrast, in the case of the K199A substitution, the 4Z,15Z-BR -CD spectra was 
altered and resembled the form typical for the M enantiomer. As illustrated in figure 4C, essentially the same 
observations were made for full body HSA, i.e., the substitution of Lys195 with an alanine has a small effect 
on the CD spectra, whereas the same type of substitution for Lys199 has a dramatic, inverting effect on the 
4Z,15Z-BR -CD spectra. The relatively small amplitudes observed for the wild type and K195A domain II 
preparations can be attributed to the weaker binding of the P form of 4Z,15Z-BR to these domain 
preparations and / or that the bend angle between the two dipyrrole chromophores of 4Z,15Z-BR had been 
modified.  
A similar mutation-induced trend was found for the domain II preparations as for the full body HSAs 
both with respect to changes in binding (Fig. 3A and B) and with respect to changes in the CD spectra for 
bound 4Z,15Z-BR (Fig. 4B and C). These findings indicate that the high-affinity 4Z,15Z-BR site is contained 
within domain II. However, because the changes are quantitatively different, the detailed structure of the 
4Z,15Z-BR -domain II complex is most probably different from those formed with full body HSA. 
 
4Z,15Z-BR binding to recombinant domain I 
The binding of 4Z,15Z-BR to wild type domain I (residues 1-186) is significantly lower than binding to 
wild type domain II. Furthermore, 4Z,15Z-BR, when bound to domain I, adopts an unusual M-conformation 
which is quite different from the typical P-conformation when binding to domain II and full body HSA (Fig. 
 
 
5A and B). 
 
4Z,15Z-BR binding to albumins of different species 
HSA shows the highest binding affinity for 4Z,15Z-BR, follow by albumins from bovine and sheep. 
Dog albumin shows the weakest binding affinity for 4Z,15Z-BR (Fig. 6A). As shown in figure 6B and S4, 
the preferred binding conformation for dog and rat albumins is the P-form, whilst the M-form is the preferred 
binding conformation for bovine and sheep albumins.  
 
Photoconversion of 4Z,15Z-BR bound to HSA, albumins of different species or HSA mutants 
4Z,15Z-BR bound to wild type HSA and the K195A mutant showed a more rapid photoconversion rate 
than that for the K199A mutant (Fig. 7A). On the other hand, HSA and dog albumin showed a faster 
photoconversion rate than bovine and sheep albumins (Fig. 7B). 
 
Discussion 
Identification of the key 4Z,15Z-BR binding amino acid residues in domain II of HSA with phage 
display 
The use of a phage display permitted the presentation of (poly) peptides as fusion bodies to capsid proteins 
on the surface of bacterial viruses or phage particles. The novel display formats, in vitro selection via 
innovative library designs and screening strategies, enabled the rapid identification and optimization of 
proteins based on their structural or functional properties. Recombinant techniques have been developed to 
increase the diversity of the library. Phage display technology has been used to develop polypeptides with 
novel properties and small antibodies such as scFv. There are some examples of "non-antibody" proteins that 
are macromolecular proteins displayed on a phage such as protective antigen protein domain 4 (24kDa) [19], 
insulin-like growth factor I (14.5 kDa) [20], human growth hormone (22 kDa) [21] and glutathione 
S-transferase (25 kDa) [22].  
 
 
HSA is a single stranded polypeptide that folds to form a heart shape protein containing 3 homologous 
domains. A HSA fragment comprised mainly of domain II has been shown to house the primary binding site 
for 4Z,15Z-BR [24]. The aim of this study was to identify amino acid residues in HSA-domain II that are of 
importance for the high-affinity binding of the 4Z,15Z-BR. In a previous study, Dockal et al. successfully 
expressed and characterized each individual HSA domain [25]. Therefore, taking advantage of the fact that 
each of the three HSA domains can be independently produced using recombinant techniques without 
significant disruption of the secondary and tertiary structures, it was possible to display a large number of 
domain II mutants on the phage and screen for candidate residues for 4Z,15Z-BR binding.  
Libraries with various biases can be created for specific purposes when the sequence of the peptide that 
binds to the target is known, and its affinity can be selectively increased by screening libraries created with 
limited mutagenesis of the peptide. In this study, the lysine and arginine codons located in subdomain IIA 
were replaced with RRA (where R represents A / G) in the cDNA library. Because RRA encodes only four 
codons (AAA: Lys, AGA: Arg, GAA: Glu, GGA: Gly), the bias of this library is considered to be 
insignificant. Figure S3 shows the sequences of the unselected library phages that display little or no bias. 
This phage library was composed of approximately 1.7 × 107 clones. A reasonably sized, diverse library 
ensures that every possible clone is represented in the library. In fact, the input phage number at round 1 was 
3.0 × 1013 (TU) which is sufficient to cover the diversity requirement of a phage library (Table 1). Using the 
phage library, the screening results indicated that Lys195 and Lys199 in the native HSA-subdomain IIA 
appeared to play an important role in the binding of BR, which contains two free carboxyl groups. Based on 
the phage display results, the role of Lys195 and Lys199 in binding 4Z,15Z-BR was further examined by 
site-directed mutagenesis. 
 
Binding affinity of 4Z,15Z-BR to HSA 
The findings reported so far indicate that mutations of Lys195 and Lys199 in subdomain IIA of HSA to 
alanine residues caused an increase in the concentration of unbound 4Z,15Z-BR, indicating that both lysine 
residues are involved in the binding of 4Z,15Z-BR (Table 2). However, a similar investigation of the wild 
type standalone domain II protein showed the binding affinity to be lower, only 1.93 ± 0.26 × 107 M-1 (Table 
 
 
2). A possible explanation for the weaker binding to the standalone domain II protein is that the BR binding 
site is more exposed to the solvent in the absence of domain I and III. A similar observation has been 
reported by Dockal et al. on the binding of site I ligand, warfarin, where the primary warfarin binding site is 
centered around subdomain IIA with indispensable structural contributions from subdomain IIB and domain 
I [25]. We also reported previously that the recombinant albumin domain II protein binds warfarin and 
DNSA only negligibly [26]. This indicates that the integrity of the binding pocket in domain II is affected by 
interdomain interactions between domains I and III. 
Goncharova and Urbanová [27] proposed that ligands with a carboxylate group may interact with the 
positively charged Lys199, Arg222 and Arg257 residues in subdomain IIA. On the other hand, in an x-ray 
crystallographic study, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), a dicarboxylic 
acid-containing renal toxin, has been shown to have five hydrogen-bond or salt-bridge interactions with 
Tyr150, Lys199, Arg222, His242 and Arg257 [28]. In a previous study, we found that CMPF competitively 
inhibited the binding of 4Z,15Z-BR to HSA [11]. Inspection of the CMPF-HSA x-ray crystallographic 
structure revealed that CMPF interacts electrostatically with Lys199 but obvious interactions with Lys195 
are lacking (Fig. 8B). These findings provide further support for the essential role of Lys199 in the binding 
of 4Z,15Z-BR. 
The importance of Lys199 over Lys195 was clearly observed from the 3rd panning results where clone 3 
retained an arginine at 199 but a glycine was located at position 195. In addition, the concentration of free 
4Z,15Z-BR for K199A was higher than that for K195A and wild type HSA in this study. In an x-ray 
crystallographic study of drug-HSA complexes, Ghuman reported that the polar groups of Lys199 and 
Lys195 were clustered with other polar amino acid residues at the entrance of the binding pocket of 
subdomain IIA, whilst only the aliphatic portion of Lys199, which contributes to the delineation of the 
subchamber, protrudes from the front of the pocket [28]. This shows that Lys199 plays more than one role in 
the binding of 4Z,15Z-BR. 
Petersen et al. [8] studied the binding of 4Z,15Z-BR to HSA preparations with several single-amino acid 
substitutions, including K195M and K199M, and found that none of the mutants had a significantly altered 
affinity for 4Z,15Z-BR. This is in contrast to the present study, in which we found that the binding of 
 
 
4Z,15Z-BR to K195A and K199A was diminished (Table 2). A comparison of the binding results for 
methionine and alanine mutants illustrate the importance of having the space at position 195 and 199 
occupied by an aliphatic side chain in order to retain 4Z,15Z-BR at the binding pocket. This can most likely 
be attributed to hydrophobic interactions. In a study using molecular dynamics modeling, Diaz et al. reported 
that Lys195 and Lys199 could play a combined and comparable chemical role in maintaining a positive 
charge, whereby a potential Lys195 → Lys199 proton-transfer process via water bridges has been proposed 
[15]. The model illustrates the complexity of the key residue, Lys199, ionization state and the nearby Lys195 
has on the structure and dynamics of the IIA binding site.  
 
Enantioselective binding of 4Z,15Z-BR to HSA 
The fully protonated unconjugated 4Z,15Z-BR diacid and the dianion adopt a folded biplanar ridge-tile 
structure analogous to a half-opened book which is stabilized through intramolecular hydrogen bonding of 
each of the two carboxylate groups to the oxygen and nitrogen of the opposing dipyrrole (Fig. 4A). This 
explains the considerable lipophilicity of the pigment compared to its biogenetic precursor biliverdin and is a 
dominant factor in its metabolism, antioxidant behavior, and toxicity [1]. The right-handed configuration is 
denoted as P (plus) and the left handed one as M (minus), referred to as the P-helicity folded conformer 
(P-form) and the M-helicity folded conformer (M-form) [29]. In solution at 37°C, the two mirror-image 
forms interconvert rapidly, forming a 50:50 mixture of P and M conformers. Nevertheless, when a chiral 
complexation agent such as serum albumin is added, the equilibrium shifts toward either the M or P 
enantiomer. In such cases one observes typically intense bisignate CD cotton effects. The conformational 
structure of the bound pigment, hence the shape and nature of the binding site on HSA can be inferred from 
the CD data [13]. 
As evidenced from the 4Z,15Z-BR-induced CD spectra, mutations of Lys195 and Lys199 to alanine 
effectively changed the binding microenvironment of the 4Z,15Z-BR binding site to different extents 
depending on the location of the mutation and, thus, the preferred binding conformation of 4Z,15Z-BR. The 
preferred binding conformation of BR by wild type HSA is the P-form, as shown in figure 4C. The mutation 
on K195A had only a minor decreasing effect on the intensities of the spectra, and the P-form of 4Z,15Z-BR 
 
 
remains the preferred binding conformation at the binding site (Fig. 4C). However, when Lys199 is 
substituted with an alanine, the spectra for 4Z,15Z-BR changed dramatically, indicating that the M-form was 
the preferred binding conformation in the absence of a lysine aliphatic side chain at location 199. A similar 
binding chirality preference could also be observed for the wild type, K195A and K199A recombinant 
domain II proteins (Fig. 4B). 
Interestingly, albumins of different species also showed such preferred binding conformation of 
4Z,15Z-BR depending of the species. Pistolozzi et al. reported that induced CD spectra of 4Z,15Z-BR bound 
to rat albumin was observed as P-form [9], which is in agreement with our finding. As shown in figure 6B 
and S4, the P-form is the preferred binding conformation for human, dog and rat albumins whilst the M-form 
is the preferred binding conformation for bovine and sheep albumins (Fig. 6B and S4). A trend was found 
when the amino acid sequences of the albumins were compared where the preferred P-form of albumins of 
humans and dogs contain lysines at positions 195 and 199, the rat albumin contains an arginine at 195 [9], 
while bovine and sheep albumins, with the M-form preferred, contain arginines at position 195 and 199 
(Table 3). Hence, Lys199 is a key amino residue responsible for P-form preferred binding conformation of 
4Z,15Z-BR by albumin. Since the mutation of lysine to methionine at position 199 had no effect on changing 
the P-form binding preference of HSA in the point mutation study reported by Petersen [8], this provides a 
demonstration of the role of an aliphatic side chain at position 199 in determining the helicity of 4Z,15Z-BR 
in the binding preference of albumin.   
Albumin has been found to facilitate a conformational change in 4Z,15Z-BR into a more water soluble 
form during phototherapy [5]. The physiological significance of the preference for a 4Z,15Z-BR binding 
conformation by albumin was evident in a further investigation of the effect of photoirradiation on 
4Z,15Z-BR and albumin mixtures. In general, the P-form preferred binding albumins facilitated a faster 
transformation of the low solubility 4Z,15Z-BR into more water soluble forms of 4Z,15Z-BR, as shown in 
figure 7B for the human and dog. A similar observation was obtained when both wild type and K195A 
mutant HSA that preferentially bind the P-form exhibited a faster transformation of 4Z,15Z-BR. In contrast, 
the mutation of Lys199 to alanine effectively changed the binding preference to the M-form, and thus a 
slower photoconversion rate of the low solubility 4Z,15Z-BR (Fig. 7A). This observation also points to the 
 
 
importance of an aliphatic side chain at position 199 for the efficient photoconversion of 4Z,15Z-BR to 
occur. 
Zunszain et al. [30] recently published a crystallographic analysis of HSA complexed with 4Z,15E-BR 
(Fig. 8A). The analysis revealed that this isomeric form of the pigment binds with a high affinity to a pocket 
in subdomain IB, and that the carboxylate groups enter into salt-bridges with arginine residues at position 
117 and 186 but not to lysine residues. Our results showed that 4Z,15Z-BR binds to domain I with a lower 
affinity than to domain II (Fig. 5A) and in an atypical M-helicity conformation instead of the usual P-form 
(Fig. 5B). Thus it is possible that subdomain IB is a binding site for 4Z,15E-BR, but may not be the primary 
high affinity binding site for 4Z,15Z-BR. However, further investigations will be needed to investigate the 
possible photoconversion of 4Z,15Z-BR to 4Z,15E-BR that leads to a shift in the binding site from 
subdomain IIA to subdomain IB.  
 
Potential clinical usefulness of domain II in hyperbilirubinemia 
The present work laid the groundwork for development of new therapeutic agents for treating jaundiced 
newborns. The major treatment for 4Z,15Z-BR-induced encephalopathy in newborns and especially in 
premature infants is phototherapy, which converts 4Z,15Z-BR, which primarily binds to its high affinity 
HSA binding site into more soluble nontoxic structural isomers that are more easily eliminated from the 
circulatory system. The rate of formation of isomers and the isomeric composition of the reaction products 
have been shown to be highly dependent on the conformation and electronic environment of 4Z,15Z-BR 
bound to HSA [8, 31]. The results of this study show that the P-form of 4Z,15Z-BR is more readily 
converted into photoisomers with higher water solubility than the M-form (Fig. 7). In a previous study, we 
reported that there was about a 50-fold difference in total clearance between HSA and individual 
recombinant domains including domain II [26]. Similar observations have been reported by Sheffield et al. 
using recombinant domains of rabbit serum albumin [32]. This indicates that HSA-domain II with preserved 
Lys199 could be useful in treating jaundiced newborns without being dependent on a premature liver, 
because it preferentially binds the P-form of 4Z,15Z-BR with a comparable high affinity, and more 






Using a phage display system, we have successfully displayed domain II of HSA on M13 phages and 
identified two key lysine residues, K195 and K199, that are involved in the binding of 4Z,15Z-BR. Further 
investigations indicated that K199 plays additional roles, compared to K195, in that it is a determinant of the 
helicity of  the P-form of 4Z,15Z-BR, which affects the binding preference of albumin, thus leading to a 
more rapid photoconversion of 4Z,15Z-BR into a more water soluble molecule for subsequent renal 
elimination.  
 
Materials and Methods 
 
Construction of a Phage Library Displaying Recombinant HSA-domain II 
HSA-domain II cDNA containing sites for restriction enzymes Sfi I and Not I, located at the N and C 
terminus, respectively, was constructed. The plasmid pCANTAB 5E also contained Sfi I and Not I sites, and 
both HSA-domain II cDNA and pCANTAB 5E were digested with Sfi I / Not I and ligated using T4 DNA 
ligase. Plasmid pCANTAB 5E encoding HSA-domain II, in which the C terminus of HSA-domain II was 
fused to the N terminus of the M13 phage gene 3 signal sequence, was confirmed by DNA sequence 
analysis.  
Oligos 1-6 were designed to have the sequence “RRA” (or TYY in the complementary strand), where R 
and Y represent G / A and C / T, respectively, at the HSA-subdomain IIA codons for Lys190, Lys195, 
Arg197, Lys199, Lys205, Arg209, Lys212, Arg218, Arg222, Lys225, Lys233 and Lys240. The sequence 
RRA can randomly encode for Lys, Arg, Gly and Glu, without bias.  
Oligo 1: 5’-CCGGCCATGTCCGATGAAGGGRRAGCTTCGTCGTCTGCC-3’ 
Oligo 2: 5’-TTGGAGACTGGCACATYYGAGTYYCTGTYYGGCAGACGAAGC-3’ 
Oligo 3: 5’-GTGCCAGTCTCCAARRATTTGGAGAARRAGCTTTCRRAGCATGGGCAGTAGCT-3’ 




Oligo 5: 5’-GCTGAGTTTGCAGAAGTTTCCRRATTAGTGACAGATCTT-3’ 
Oligo 6: 5’-GCAGCATTCCGTGTGGACTYYGGTAAGATGTGTCACTAA-3’ 
HSA_d II_Sfi I: 5’-CCTTTCTATGCGGCCCAGCCGGCCATGTCCGATGAA-3’ 
HSA_d II_120r: 5’-GGAAACTTCTGCAAACTCAGC-3’ 
HSA_d II_Nco I: 5’- CAGATCTCCATGGCAGCATTCCGTGTGGAC-3‘ 
Mutagenic double-strand DNAs were synthesized from these oligonucleotides using Klenow fragment 
(TaKaRa, Kyoto, Japan). Prepared double-strand DNAs with oligo 1-2, 3-4 and 5-6 are denoted as fragment 
1, 2, 3, respectively (Fig. S1).  
To identify key residues of importance for the binding of BR to HSA, we prepared a HSA display phage 
library. Because it is most likely that the present isomer of BR binds to domain II, we proceeded to display 
that domain. As seen in figure S1, the synthesized double-strand DNA fragments were elongated and 
amplified by PCR using PfuUltra High-Fidelity DNA polymerase (Stratagene, La Jolla, CA, USA). Finally, 
mutagenized HSA-subdomain IIA cDNA was ligated into pCANTAB 5E. 
 
Biopanning 
200 μl of BR coupling gel was blocked with 1 ml of 0.5% gelatin overnight at room temperature. 1 ml of 
the phage library was added to the gel, which was then allowed to bind for 2 h at 37°C. After binding, the gel 
was washed 3 or 10 times with PBS containing 0.005% Tween 20 and eluted with 1 mL of 0.1 M 
Glycine-HCl (pH 2.2) containing 1 mg / mL BSA. The eluate was collected and neutralized with 60 μl of 2 
M Tris-HCl. The eluted phages were amplified and used for next-round selection.  
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TABLE 1 Enrichment of the phage library from round 1 to 3 expressed as recovery rate. 
Rounds Input phage (TU) Output phage (TU) Recovery rate (Per 105 phages) 
1 3.0 × 1013 1.2 × 109 4.0 
2 2.2 × 1012 1.4 × 107 0.63 




TABLE 2 BR affinity binding constants of recombinant domain II and HSA (WT, K195A, K199A). 
 HSA 
Ka [× 107 (M-1)] 
Domain II 
Ka [× 107 (M-1)] 
WT 5.03 ± 0.53 1.93 ± 0.26 
K195A 1.10 ± 0.32 0.327 
K199A 1.01 ± 0.15 0.209 
 
BR binding to different recombinant domain II and HSA preparations studied with the fluorescence 
enhancement titration technique. The protein solutions were excitated at 460 nm, and the emission was 
measured at 512 nm in the case of wild type HSA and K199A mutant, and at 507 nm in the case of the 
K195A mutant. The protein concentration was kept constant at 3 µM, whereas the concentration of BR was 
varied from 0 to 3.0 µM; the medium was 67 mM sodium phosphate buffer, pH 7.4. Data are expressed as 




TABLE 3 Amino acid residues at positions 195 and 199 of albumins of different species and the 
corresponding BR binding helicity form. 
Mammalian Homology (%) BR helicity 195 199 222 
Human 100 P K K R 
Dog 80 P K K R 
Rat 73 P (Fig. S1, [9]) R K R 
Bovine 75 M R R K 





Fig. 1. Detection of domain II display phage. (A) Various concentrations of phage solutions were plated on 
96-well microtiter plates at 100 µL / well. After an overnight incubation, the wells were washed and blocked 
with 0.5% gelatin, and treated with a HRP-conjugated anti-M13KO7 antibody. (B) Various concentrations of 
phage solutions were plated on 96-well microtiter plates at 100 µL / well. After an overnight incubation, the 
coated wells were washed and blocked with gelatin, followed by reaction with anti-HSA polyclonal antibody. 
Color development was with 5-amino-2-hydroxybenzoic acid, and 0.02% H2O2 was used as a chromogen. 
 
Fig. 2. Selection and confirmation of domain II clones that bind 4Z,15Z-BR. (A) Partial amino acid 
sequences of domain II clones selected after 3 rounds of panning on 4Z,15Z-BR. (B) 4Z,15Z-BR binding to 
domain II clones as determined by a HRP assay. The molar ratio between 4Z,15Z-BR and protein was 2:1, 
and the concentration of unbound ligand is shown. Protein solutions were plated on 96-well microtiter plates 
at 100 µL / well. After a 2 hr incubation, the coated wells were washed, and 60 µM 4Z,15Z-BR was added to 
each well. Then, 10 µL of 1.75 mM H2O2 and 10 µl of 1 ng / mL HRP were added, and the absorbance at 450 
nm was recorded. The free 4Z,15Z-BR concentrations were estimated as described in Experimental 
Procedures. Data are expressed as means ± SEM (n = 3). When the results obtained for the mutated domain 
II clones were compared to those obtained for the wild type domain II clone (No. 7), the p-values were in all 
cases > 0.05. 
 
Fig. 3. 4Z,15Z-BR binding properties of recombinant domain II and HSA (WT, K195A, K199A). The 
concentration of unbound 4Z,15Z-BR in the presence of recombinant domain II proteins (A) or recombinant 
HSA proteins (B) determined by the HRP assay. 60 µM 4Z,15Z-BR was incubated with 30 µM of domain II 
proteins or to 15 µM HSA proteins, each dissolved in 67 mM phosphate buffer (pH7.4). The free 4Z,15Z-BR 
concentrations were estimated as described in Experimental Procedures. Data are expressed as means ± SEM 




Fig. 4. Induced CD spectra of 4Z,15Z-BR bound to recombinant domain II and HSA (WT, K195A, K199A). 
(A) Structures of the M and P enantiomers of 4Z,15Z-BR. The “ridge-tile” conformations are indicated. (B) 
CD spectra of 4Z,15Z-BR bound to different versions of domain II. (C) CD spectra of 4Z,15Z-BR bound to 
different HSAs. Common to (B) and (C), 800 µL of a 40 µM domain II solution or a 20 µM HSA solution in 
67 mM sodium phosphate buffer (pH7.4), was placed in a 1.0-cm pathlength cell and scanned from 350 to 
550 nm. 4Z,15Z-BR was subsequently added to a final concentration of 60 µM or 30 µM, respectively. After 
mixing and then standing for 10 min, the samples were re-scanned from 350 to 550 nm.  
 
Fig. 5. 4Z,15Z-BR binding properties of recombinant domain I compared to domain II and HSA. (A) The 
concentration of unbound 4Z,15Z-BR in the presence of domain I or II was determined by the HRP assay. 60 
µM 4Z,15Z-BR was incubated with 30 µM of recombinant HSA, domain I and domain II in 67 mM 
phosphate buffer (pH7.4). The free 4Z,15Z-BR concentrations were estimated as described in Experimental 
Procedures. Data are expressed as means ± SEM (n = 3). (B) Induced CD spectra of 4Z,15Z-BR bound to 
wild type domain I or II or HSA. Firstly, the CD spectra were obtained by placing 800 µL of a 40 µM 
domain I or II solution or a 20 µM HSA solution in 67 mM sodium phosphate buffer, pH7.4, in a 1.0-cm 
pathlength cell and scanned from 350 to 550 nm. 4Z,15Z-BR was then added to a final concentration of 60 
µM or 30 µM, respectively. After mixing and standing for 10 min, the samples were scanned from 350 to 
550 nm.  
 
Fig. 6. 4Z,15Z-BR binding properties of albumins of different species. (A) The concentration of unbound 
4Z,15Z-BR in the presence of albumins of different species was determined by the HRP assay. 15 µM 
4Z,15Z-BR was incubated with 30 µM of albumin in 67 mM phosphate buffer (pH7.4). The free 4Z,15Z-BR 
concentrations were estimated as described in Experimental Procedures. Data are expressed as means ± SEM 
(n = 3). (B) Induced CD spectra of 4Z,15Z-BR bound to albumin of different species. The CD spectra were 
initially obtained by placing 800 µL of a 20 µM albumin solution in 67 mM sodium phosphate buffer, pH 7.4, 
in a 1.0-cm pathlength cell and the solution scanned from 350 to 550 nm. 4Z,15Z-BR was then added to a 
 
 
final concentration of 20 µM. After mixing and standing for 10 min, the samples were scanned from 350 to 
550 nm.  
 
Fig. 7. Rate of photoconversion of 4Z,15Z-BR into other more water soluble forms of BR. (A) Recombinant 
HSA and its K195A, K199A mutants and (B) albumin from different species. 
 
Fig. 8. Binding regions of 4Z,15E-BR and CMPF on HSA. Magnification of the binding region of 
4Z,15E-BR (A) and CMPF (B), with the 4 amino acid residues lining the entrance of the site I binding 
pocket in subdomain IIA, namely K195, K199, R218 and R222, shown as ball and stick models, CPK color 
style. Domain I (grey) and II (green) were displayed in back bone style while domain III (grey) in strand 
style. Both diagrams were generated with RASMOL, using the x-ray crystallographic structure data files 
from protein data bank, PDB ID: 2VUE for 4Z, 15E-BR-HSA (A) and PDB ID: 2BXA for CMPF-HSA (B). 
The insert in (A) shows whole HSA structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
